. 2020 Mar 4;11(10):2921–2934. doi: 10.7150/jca.41834

Table 2.

Univariate and multivariate survival analyses

Gene	Patients (n=500)	No. of events (%)	MST (days)	Crude HR (95% CI)	Crude P	Adjusted HR* (95% CI)	Adjusted P*
NDC80
High	250	106(42.4%)	1288	Ref. 0.661 (0.492-0.888)	0.006	Ref. 0.635 (0.419-0.962)	0.032
Low	250	76(30.4%)	1600	Ref. 0.661 (0.492-0.888)	0.006	Ref. 0.635 (0.419-0.962)	0.032
Missing	0	-	-	-	-	-	-
NUF2
High	250	107(42.8%)	1229	Ref. 0.654 (0.487-0.879)	0.005	Ref. 0.741 (0.493-1.114)	0.150
Low	250	75(30.0%)	1632	Ref. 0.654 (0.487-0.879)	0.005	Ref. 0.741 (0.493-1.114)	0.150
Missing	0	-	-	-	-	-	-
SPC24
High	250	106(42.4%)	1229	Ref. 0.662 (0.493-0.890)	0.006	Ref. 0.734 (0.490-1.099)	0.133
Low	250	76(30.4%)	1622	Ref. 0.662 (0.493-0.890)	0.006	Ref. 0.734 (0.490-1.099)	0.133
Missing	0	-	-	-	-	-	-
SPC25
High	250	108(43.2%)	1171	Ref. 0.609 (0.453-0.819)	0.001	Ref. 0.657 (0.434-0.995)	0.047
Low	250	74(29.6%)	1632	Ref. 0.609 (0.453-0.819)	0.001	Ref. 0.657 (0.434-0.995)	0.047
Missing	0	-	-	-	-	-	-

Notes: *adjustment for radiation therapy history; targeted therapy history; neoplasm status; TNM stage and residual tumors. Abbreviations: MST, median survival time; HR, hazard ratio; CI, confidence interval.